When you hear the word epilepsy, what comes to mind? For many, it rsquo;s a vague image of someone having a seizure ndash; ...

Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings and ...

NeuroPace is known for its innovative RNS System, the first brain-responsive platform that provides personalized treatment to manage seizures in patients with drug-resistant epilepsy, potentially ...

Q4 2024 Earnings Call Transcript March 4, 2025 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

“We are pleased by the interest in our recent financing and the confidence it shows in our mission to transform the lives of people suffering from drug-resistant epilepsy through RNS ® therap ...

In response to these suggestions, a core group of 24 RNs volunteered to receive additional education related to epilepsy and best-practice PEMU care. The education program for the core group was ...

NeuroPace Inc (NPCE) reports a 22% annual revenue increase and outlines strategic initiatives for continued growth in 2025.

“We have several ongoing clinical programs examining the RNS System in expanded patient populations and new indications in epilepsy that are expected to announce data or have regulatory events ...

RN reviews safety, expectations ... Buchhalter, PhD MD, is the former director of the pediatric epilepsy program in the Mayo Clinic Department of Neurology, Rochester, MN.